UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic

Current treatment options in oncology, 2021-10, Vol.22 (10), p.93-93, Article 93

2021

Volltextzugriff (PDF)

The Role of Immunotherapy in Pancreatic Cancer

Current oncology (Toronto), 2022-09, Vol.29 (10), p.6864-6892

2022

Volltextzugriff (PDF)

Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives

Cancers, 2020-07, Vol.12 (8), p.2001

2020

Volltextzugriff (PDF)

The current state of molecular profiling in gastrointestinal malignancies

Biology direct, 2022-06, Vol.17 (1), p.15-22, Article 15

2022

Volltextzugriff (PDF)

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis

Cancers, 2023-03, Vol.15 (6), p.1831

2023

Volltextzugriff (PDF)

Establishing the feasibility of a patient-engagement tool to improve outpatient symptom management and dosing of patients on regorafenib

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.417-417

2022

Volltextzugriff (PDF)

Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS765-TPS765

2024

Volltextzugriff (PDF)

Evolving applications of liquid biopsies in gastrointestinal cancers

Clinical advances in hematology & oncology, 2024-01, Vol.22 (1), p.43-54

2024

Volltextzugriff (PDF)

Prognostic utility of preoperative and postoperative circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.595-595

2022

Volltextzugriff (PDF)

Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

Surgical oncology, 2023-12, Vol.51, p.102007-102007, Article 102007

2023

Volltextzugriff (PDF)

Impact of next-generation sequencing in biliary tract cancer treatment

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.560-560

2024

Volltextzugriff (PDF)

Microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) across gastrointestinal (GI) malignancies

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.176-176

2024

Volltextzugriff (PDF)

Immunotherapy for Colorectal Cancer

Hematology/oncology clinics of North America, 2022-06, Vol.36 (3), p.603-626

2022

Volltextzugriff (PDF)

Microscopic residual disease (MRD) monitoring and time to disease recurrence across gastrointestinal (GI) malignancies: A single-institution, real-world study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15518-e15518

2023

Volltextzugriff (PDF)

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4194-TPS4194

2023

Volltextzugriff (PDF)

Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4087-4087

2023

Volltextzugriff (PDF)

Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.805-805

2023

Volltextzugriff (PDF)

Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.789-789

2023

Volltextzugriff (PDF)

Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4198-TPS4198

2024

Volltextzugriff (PDF)

The gut microbiome and potential implications for early-onset colorectal cancer

Colorectal cancer, 2020-10, Vol.9 (3)

2020

Volltextzugriff (PDF)

The roles of race and social determinants of health in pancreatic adenocarcinoma diagnosis and treatment

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18565-e18565

2023

Volltextzugriff (PDF)

A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16288-e16288

2023

Volltextzugriff (PDF)

Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review

Journal of thoracic disease, 2023-06, Vol.15 (6), p.3466-3487

2023

Volltextzugriff (PDF)

Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers

Oncology & Haematology, 2022, Vol.18 (1), p.26

2022

Volltextzugriff (PDF)

Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.287-287

2023

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic

The Role of Immunotherapy in Pancreatic Cancer

Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives

The current state of molecular profiling in gastrointestinal malignancies

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis

Establishing the feasibility of a patient-engagement tool to improve outpatient symptom management and dosing of patients on regorafenib

Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease

Evolving applications of liquid biopsies in gastrointestinal cancers

Prognostic utility of preoperative and postoperative circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

Impact of next-generation sequencing in biliary tract cancer treatment

Microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) across gastrointestinal (GI) malignancies

Immunotherapy for Colorectal Cancer

Microscopic residual disease (MRD) monitoring and time to disease recurrence across gastrointestinal (GI) malignancies: A single-institution, real-world study

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC)

Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer

Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC)

Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study

Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence

The gut microbiome and potential implications for early-onset colorectal cancer

The roles of race and social determinants of health in pancreatic adenocarcinoma diagnosis and treatment

A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma

Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review

Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers

Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC)

Suchergebnisse filtern